Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1136/thx.2009.118588. Epub 2009 Aug 23.
Affiliations
- PMID: 19703825
- DOI: 10.1136/thx.2009.118588
Randomized Controlled Trial
Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia
M Falguera et al. Thorax. 2010 Feb.
Abstract
Background: Recommendations for diagnostic testing in hospitalised patients with community-acquired pneumonia remain controversial. The aim of the present study was to evaluate the impact of a therapeutic strategy based on the microbiological results provided by urinary antigen tests for Streptococcus pneumoniae and Legionella pneumophila.
Methods: For a 2-year period, hospitalised patients with community-acquired pneumonia were randomly assigned to receive either empirical treatment, according to international guidelines, or targeted treatment, on the basis of the results from antigen tests. Outcome parameters, monetary costs and antibiotic exposure levels were compared.
Results: Out of 194 enrolled patients, 177 were available for randomisation; 89 were assigned to empirical treatment and 88 were assigned to targeted treatment. Targeted treatment was associated with a slightly higher overall cost (euro 1657.00 vs euro 1617.20, p=0.28), reduction in the incidence of adverse events (9% vs 18%, p=0.12) and lower exposure to broad-spectrum antimicrobials (154.4 vs 183.3 defined daily doses per 100 patient days). No statistically significant differences in other outcome parameters were observed. Oral antibiotic treatment was started according to the results of antigen tests in 25 patients assigned to targeted treatment; these patients showed a statistically significant higher risk of clinical relapse as compared with the remaining population (12% vs 3%, p=0.04).
Conclusions: The routine implementation of urine antigen detection tests does not carry substantial outcome-related or economic benefits to hospitalised patients with community-acquired pneumonia. Narrowing the antibiotic treatment according to the urine antigen results may in fact be associated with a higher risk of clinical relapse.
Comment in
Similar articles
- [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
Roger PM, Risso K, Hyvernat H, Landraud L, Vassallo M, Dellamonica J, de Salvador F, Cua E, Bernardin G. Roger PM, et al. Med Mal Infect. 2010 Jun;40(6):347-51. doi: 10.1016/j.medmal.2010.01.005. Epub 2010 Feb 20. Med Mal Infect. 2010. PMID: 20172672 French. - Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
Mykietiuk A, Carratalà J, Fernández-Sabé N, Dorca J, Verdaguer R, Manresa F, Gudiol F. Mykietiuk A, et al. Clin Infect Dis. 2005 Mar 15;40(6):794-9. doi: 10.1086/428059. Epub 2005 Feb 17. Clin Infect Dis. 2005. PMID: 15736010 Clinical Trial. - [Community-acquired pneumonia due to Legionella pneumophila serogroup 1. Study of 97 cases].
Benito JR, Montejo JM, Cancelo L, Zalacaín R, López L, Fernández Gil de Pareja J, Alonso E, Oñate J. Benito JR, et al. Enferm Infecc Microbiol Clin. 2003 Oct;21(8):394-400. Enferm Infecc Microbiol Clin. 2003. PMID: 14525703 Review. Spanish.
Cited by
- Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.
Navarro-Torné A, Montuori EA, Kossyvaki V, Méndez C. Navarro-Torné A, et al. Hum Vaccin Immunother. 2021 Oct 3;17(10):3670-3686. doi: 10.1080/21645515.2021.1923348. Epub 2021 Jun 9. Hum Vaccin Immunother. 2021. PMID: 34106040 Free PMC article. - Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.
de With K, Allerberger F, Amann S, Apfalter P, Brodt HR, Eckmanns T, Fellhauer M, Geiss HK, Janata O, Krause R, Lemmen S, Meyer E, Mittermayer H, Porsche U, Presterl E, Reuter S, Sinha B, Strauß R, Wechsler-Fördös A, Wenisch C, Kern WV. de With K, et al. Infection. 2016 Jun;44(3):395-439. doi: 10.1007/s15010-016-0885-z. Infection. 2016. PMID: 27066980 Free PMC article. - Multiplex real-time PCR in non-invasive respiratory samples to reduce antibiotic use in community-acquired pneumonia: a randomised trial.
Abelenda-Alonso G, Calatayud L, Rombauts A, Meije Y, Oriol I, Sopena N, Padullés A, Niubó J, Duarte A, Llaberia J, Aranda J, Gudiol C, Satorra P, Tebé C, Ardanuy C, Carratalà J. Abelenda-Alonso G, et al. Nat Commun. 2024 Aug 17;15(1):7098. doi: 10.1038/s41467-024-51547-8. Nat Commun. 2024. PMID: 39154071 Free PMC article. Clinical Trial. - Urinary Antigen Testing for Respiratory Infections: Current Perspectives on Utility and Limitations.
Kim P, Deshpande A, Rothberg MB. Kim P, et al. Infect Drug Resist. 2022 Apr 27;15:2219-2228. doi: 10.2147/IDR.S321168. eCollection 2022. Infect Drug Resist. 2022. PMID: 35510157 Free PMC article. Review. - Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Metlay JP, et al. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. Am J Respir Crit Care Med. 2019. PMID: 31573350 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical